A mass in the axilla can be caused by many different things, many of them not related to the breast, however current Trust referral guidelines state that they need to be referred to the NBT Breast Care Centre for a clinical examination of breast and axilla with imaging including an axillary USS, to rule out breast cancer. Although GPs can request axillary USS on ICE, requests which may be breast related or for likely lymph nodes, not thought to be lymphoma, will be bounced and sent to the Breast Care Centre.
More common differential diagnoses;
Axillary Lymph Node
Sebaceous Cyst and other skin related lesions
Accessory Breast Tissue – felt as a diffuse mass in the lower axilla. Often changes cyclically and common in pregnancy.
Benign neoplasms (rare, often related to neural tissue – schwannomas)
Post-operative changes (seroma/lymphocele)
The following patients should be referred to the Breast Care Centre via 2WW:
Palpable axillary lymph nodes with concerning history such as :
Exclusions:
Skin lesions (infected sebaceous cyst, hidradenitis suppurativa)
Within 2 weeks of a vaccination to ipsilateral arm or trauma / injury to ipsilateral limb (bite/animal scratch). Please clinically re-evaluate in 4 weeks, and if persists can then be referred.
Axillary masses with concerning history (see above) should be referred urgently using 2WW breast referral form.
For suspected lymphoma, please refer to haematology 2WW
For suspected skin malignancy, please refer to dermatology 2WW
For suspected TB, please refer to respiratory team
For suspected non-breast malignancy/metastatic spread, please refer to the appropriate specialist.
History, important questions to ask;
Examination;
Refer to the Bristol Breast Care Centre using the 2WW referral form
Efforts are made to ensure the accuracy and agreement of these guidelines, including any content uploaded, referred to or linked to from the system. However, BNSSG ICB cannot guarantee this. This guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer, in accordance with the mental capacity act, and informed by the summary of product characteristics of any drugs they are considering. Practitioners are required to perform their duties in accordance with the law and their regulators and nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.
Information provided through Remedy is continually updated so please be aware any printed copies may quickly become out of date.